- Novo and Lilly soar up the company charts, having just entered the top 10 last year.
- Resurgent CNS and respiratory are both prominent among most valuable pipeline candidates.
- The prescription drug market will hit $1.7 trillion.
On-Demand Webinar
World Preview 2024: Pharma’s Growth Boost
Are you ready to look at the pharma landscape through a long-range lens?
Evaluate has released new forecasts out to 2030. With obesity, immuno-inflammation and oncology driving an increase in CAGR to 2030 of 7.7%, the panel will discuss what this means for the 10 top-selling therapies and the domination of the so-called ‘big drugs for big diseases’.
Watch the Webinar
What to Expect
Our Experts
Melanie Senior
Author, World Preview
Dan Chancellor
VP Norstella Thought Leadership
